Abstract
The “cure” for the ever rising cost of in vitro ADME screening performed to support drug discovery may be readily at hand. Rationally putting into practice and real use existing in silico technology based on available ADME data can reduce costs in terms of volume of ADME screening and in some cases compound generation (potential compounds predicted to have poor attributes would not be synthesized). It is clear that in order for an in silico model to be successful; its development must require not only reliable and relevant data input, but also clarity and realistic expectations of its output. This work focuses on the development and application of an in silico passive apparent permeability (Papp) model, created with a specific purpose and end user in mind (i.e., medicinal chemist & pharmacokineticist working in early drug discovery). In addition, this work describes how this in silico model can be used in combination with experimental permeability screens such as PAMPA (Parallel Artificial Membrane Permeability Assay) & MDCK (Madin Darby Canine Kidney) cells to further guide drug discovery while enabling a resource sparing approach.
Keywords: ADME, Permeability, In silico, Caco-2, MDCK, Pampa, Computational
Letters in Drug Design & Discovery
Title: Moving in Silico Screening into Practice: A Minimalist Approach to Guide Permeability Screening!!
Volume: 3 Issue: 8
Author(s): Chad L. Stoner, Mathew Troutman, Hua Gao, Kjell Johnson, Charles Stankovic, Joanne Brodfuehrer, Eric Gifford and Man Chang
Affiliation:
Keywords: ADME, Permeability, In silico, Caco-2, MDCK, Pampa, Computational
Abstract: The “cure” for the ever rising cost of in vitro ADME screening performed to support drug discovery may be readily at hand. Rationally putting into practice and real use existing in silico technology based on available ADME data can reduce costs in terms of volume of ADME screening and in some cases compound generation (potential compounds predicted to have poor attributes would not be synthesized). It is clear that in order for an in silico model to be successful; its development must require not only reliable and relevant data input, but also clarity and realistic expectations of its output. This work focuses on the development and application of an in silico passive apparent permeability (Papp) model, created with a specific purpose and end user in mind (i.e., medicinal chemist & pharmacokineticist working in early drug discovery). In addition, this work describes how this in silico model can be used in combination with experimental permeability screens such as PAMPA (Parallel Artificial Membrane Permeability Assay) & MDCK (Madin Darby Canine Kidney) cells to further guide drug discovery while enabling a resource sparing approach.
Export Options
About this article
Cite this article as:
Stoner L. Chad, Troutman Mathew, Gao Hua, Johnson Kjell, Stankovic Charles, Brodfuehrer Joanne, Gifford Eric and Chang Man, Moving in Silico Screening into Practice: A Minimalist Approach to Guide Permeability Screening!!, Letters in Drug Design & Discovery 2006; 3 (8) . https://dx.doi.org/10.2174/157018006778194736
DOI https://dx.doi.org/10.2174/157018006778194736 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Synthesis and in vitro Antibacterial Activity of 5-Halogenomethylsulfonyl- Benzimidazole and Benzotriazole Derivatives
Medicinal Chemistry A Patient with COVID-19 Disease in a Referral Hospital in Iran: A Typical Case
Infectious Disorders - Drug Targets Antioxidant Hybrid Compounds: A Promising Therapeutic Intervention in Oxidative Stress Induced Diseases
Mini-Reviews in Medicinal Chemistry Reviewing Antiviral Research against Viruses Causing Human Diseases - a Structure-Guided Approach
Current Molecular Pharmacology Meet Our Editorial Board Member
Current Drug Safety Mechanochemical Synthesis and Reactivity of 1,2,3-Triazole Carbohydrate Derivatives as Glycogen Phosphorylase Inhibitors
Current Organic Synthesis Viral Infection - A Cure for Type 1 Diabetes?
Current Medicinal Chemistry Study of the cis-trans Isomerization of the Amino-Acyl prolyl Peptide Bond. Application to the Design of Novel Inhibitors of Immunophilins
Current Organic Chemistry Withdrawal Notice: COVID-19: Outbreak to Global
Anti-Infective Agents COVID-19 and Brain Aging: What are the Implications of Immunosenescence?
Current Aging Science Activated Surfaces for Laser Desorption Mass Spectrometry: Application for Peptide and Protein Analysis
Current Pharmaceutical Design The Synthesis of Naturally Occurring Vitamin K and Vitamin K Analogues
Current Organic Chemistry Effects of Salinomycin on Cancer Stem Cell in Human Lung Adenocarcinoma A549 Cells
Medicinal Chemistry Docking and Molecular Dynamics Simulations of Peroxisome Proliferator Activated Receptors Interacting with Pan Agonist Sodelglitazar
Protein & Peptide Letters Radar Cross Section Identification of Air Targets using the Cosine Transform and Neural Networks
Recent Patents on Engineering Thymosin α1; Potential Therapeutic Implications of an Immunoregulatory Drug in the Treatment of Lymphocytopenia Associated with COVID-19
Current Immunology Reviews (Discontinued) First Discovery of Tylophora Alkaloids as HIV Inhibitors
Letters in Drug Design & Discovery Assessing the Effectiveness of a Telemedicine Initiative in Clinical Management of Children Living with HIV/AIDS in Maharashtra, India
Current HIV Research Inhibition of Matrix Metalloproteinases as a Feasible Therapeutic Target in Rheumatoid Arthritis
Current Rheumatology Reviews Novel Drugs Targeting the SARS-CoV-2/COVID-19 Machinery
Current Topics in Medicinal Chemistry